Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VWIGE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuM25-vcMMAE-E2
|
|||||
| Synonyms |
HuM25 vcMMAE-E2; huM25 vcMMAE-E2
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 5 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Head and neck cancer [ICD11:2B60-2B6E]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
HuM25
|
Antibody Info | ||||
| Antigen Name |
Leucine-rich repeat-containing protein 15 (LRRC15)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.1
|
nM
|
HCT 116 cells
|
Colon carcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 0.00% (Day 28) | Moderate LRRC15 expression (LRRC15++; IHC 2+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in MC-38 xenografts.
|
||||
| In Vivo Model | MC-38 CDX model | ||||
| In Vitro Model | Mouse colon adenocarcinoma | MC-38 cells | CVCL_B288 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 59.41% (Day 38) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in HPAF-II xenografts.
|
||||
| In Vivo Model | HPAF-II CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 64.94% (Day 23) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 71.99% (Day 11) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 80.57% (Day 28) | Moderate LRRC15 expression (LRRC15++; IHC 2+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus anti-PD1 mAb (2 mg/kg) were demonstrated in MC-38 xenografts.
|
||||
| In Vivo Model | MC-38 CDX model | ||||
| In Vitro Model | Mouse colon adenocarcinoma | MC-38 cells | CVCL_B288 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 87.45% (Day 78) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in NW-231 xenografts.
|
||||
| In Vivo Model | PANC-1 CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 88.36 % (Day 26) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (4.5 mg/kg) was demonstrated in HN-5 xenografts.
|
||||
| In Vivo Model | HPAF-II CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 88.55% (Day 23) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus Carboplatin (50 mg/kg) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 89.39% (Day 72) | Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in PANC-1 xenografts.
|
||||
| In Vivo Model | PANC-1 CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 89.73% (Day 23) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus Cetuximab (3 mg/kg) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 90.12% (Day 30) | Moderate LRRC15 expression (LRRC15++; IHC 2+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in NW-231 xenografts.
|
||||
| In Vivo Model | NW-231 CDX model | ||||
| In Vitro Model | Triple negative breast cancer | NW231 cells | Homo sapiens | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 91.24% (Day 21) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 91.66% (Day 18) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (3 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 91.84% (Day 27) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 91.86% (Day 21) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 92.25% (Day 23) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus Radiation (15 Gy) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 92.71% (Day27) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in NCI-H1650 xenografts.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 93.56% (Day 38) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) plus Gemcitabine (80 mg/kg) were demonstrated in HPAF-II xenografts.
|
||||
| In Vivo Model | HPAF-II CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 96.35% (Day 33) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in NCI-H1650 xenografts.
|
||||
| In Vivo Model | HN-5 CDX model | ||||
| In Vitro Model | Squamous cell carcinoma | HN-5 cells | CVCL_8128 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 97.05 % (Day 16) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 98.10% (Day 21) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) plus Gemcitabine (100 mg/kg) were demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 98.18% (Day 27) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) plus Erlotinib (100 mg/kg) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 99.13% (Day 18) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (3 mg/kg) plus Docetaxel (7.5 mg/kg) were demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10 nM | Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.